2026 Q2 -tulosraportti
Vain PDF
12 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 763 | - | - | ||
| 19 000 | - | - | ||
| 1 000 | - | - | ||
| 1 000 | - | - | ||
| 3 363 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
No funds report this stock among their ten largest holdings.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 min sittenstock status Weed.de has for at least 3 weeks only had 3 pharmacies that have had the oil in stock. Now they have 4 pharmacies that have the oil in stock. I'm crossing my fingers that this is a sign that Weeco Pharma has succeeded in getting the batch released. The reason it has taken so long is that the German system that must approve the oil for sale is under pressure, after clarification on July 29. If the batch is not approved, then it must mean that this pharmacy has received approval to buy internally, probably the pharmacy in Hambrug.- ·3 t sittenOnly for those of you who don't know anything about the French market and would like to gain more knowledge. As is always the case in this industry, it's complicated, so it will be an ongoing process where we gradually become wiser about what's happening in France. There has been so much turbulence in Germany that, for my part, France has been pushed a bit into the background. But now that French politicians are returning from their summer holidays on Monday. And since everyone in Germany is taking a break, I thought I would take the opportunity to look into why PJ and TS have stated that they expect France to become a valuable market for Stenocare. Stenocare has two agreements in France. One is Institut des Cannabinoïdes Médicaux Français, the other is the distribution giant Movianto (see link below) Stenocare has, via ICMF, sent an application to HAS, because HAS has opened up for early application of medical cannabis. These companies have two different purposes. ICMF ICMF specializes in helping companies write applications, in this case, to the French "HAS" to ensure this is done correctly the first time. Movianto is one of the largest distributors in France. They state on their website: " leading specialist in supply chains within the healthcare and pharmaceutical sectors" What strikes me is that it is the pharmaceutical sector they specialize in. And as is well known, the devil is in the details. Movianto has approval to sell pharmaceutical and standardized medicines and not medical cannabis. Therefore, Astrum 10/10 can only be approved as a pharmaceutical and standardized medicine, and not cannabis medicine in France. The President has not signed yet, but it is expected to happen later and to be announced on October 1st. After that, the process towards final approval will proceed "ICMF" Their website is down, https://icmf.fr/ Movianto https://movianto.com/locations/france/ Announcement of cooperation with the above. https://www.inderes.dk/en/releases/stenocare-as-positions-for-first-mover-advantage-in-france-with-strategic-partnership-product-filing-and-national-distribution-partnership
- ·1 päivä sittenFrance has gone through a longer pilot project period, regarding medical cannabis. Concurrently, research has apparently been conducted into whether cannabis medicine could replace other medicine. They found out that it could. The study has proven that medical cannabis has reduced the consumption of opioids. After this study has emerged, French politicians have become more favorably disposed towards medical cannabis, therefore they want the pilot project to become a permanent scheme. For this reason, there will hardly be anyone who will put a spoke in the wheel to prevent the president from signing the decree, which is planned for this September. As I have written previously, flower medicine does not receive subsidies. But standardized oil, such as Astrum 10/10, will be approved for sale and receive 100% reimbursement. https://businessofcannabis.com/france-sets-july-deadline-for-medical-cannabis-regulations-as-withheld-study-shows-opioid-reductions/There is nothing decisively new to report about France. The post is only about 3D feeling a need to write something about stenocare every day and all the time.
- ·2 päivää sittenA bit of gossip from Germany while we wait for the batch to be released. There has just been a lawsuit in Frankfurt, where a woman wanted to have the opportunity to retain her status in the healthcare system regarding flower medicine. She did not win. By mistake or perhaps it was lobbying, it was also interpreted as if she and all others who had been treated with flower medicine after this ruling should be considered new patients, and then would have to go into quarantine anyway. This has been rectified again, and as of August 28th, a message has been sent out that these patient groups are free from quarantine. As long as those who have been treated with flowers before July 30th are free from quarantine, then it's good for Weeco Astrum10/10 because more bottles will be handed over the counter from this segment. https://bdcan.de/cannabisblueten-gkv/
Admitted, I was cracking up, sorry. But it was good. I'm into good humor, after all 
·28.8.I think it's a shame that this feed is completely polluted by 3D's assumptions and updates about inventory etc. It's very difficult to get an overview when there's incessant posting at all times. Could one perhaps just provide input once every 14 days? @3DSnehild, I think you should come up with some news yourself, I would welcome that, and I would also welcome others spending time to come up with news about this stock. I also think it's strange that you're angry that I spend time looking for news. Only because I have spent time looking for news, do you know that the flower medicine has lost its subsidy in Germany first on July 10th and later clarified as of July 29th, 2026. It is absolutely correct that it shouldn't have been me who broke this news. But it should have been the management who came with this news, because this news would most likely have an impact on the stock price, because Stenocare can now look forward to a larger income in Germany, which no one had expected, because this law of July 10th came suddenly, and therefore some of these will be prescribed Weeco Astrum 10/10 which is an unexpected income for Stenocare. But because it is me who broke this news and not Stenocare, it has naturally had no impact on the stock price. But if Stenocare had fulfilled their disclosure obligation, it would be likely that the stock price would have risen, due to this unexpected extra income. This has a name: asymmetric information. So yes, if Stenocare had come with this information instead of me, the stock would have been worth much more than it is now. You must take your complaints to the right place if you want it to be rectified, or keep quiet.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 625 | 44 625 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 625 | 44 625 | 0 | 0 |
2026 Q2 -tulosraportti
Vain PDF
12 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 min sittenstock status Weed.de has for at least 3 weeks only had 3 pharmacies that have had the oil in stock. Now they have 4 pharmacies that have the oil in stock. I'm crossing my fingers that this is a sign that Weeco Pharma has succeeded in getting the batch released. The reason it has taken so long is that the German system that must approve the oil for sale is under pressure, after clarification on July 29. If the batch is not approved, then it must mean that this pharmacy has received approval to buy internally, probably the pharmacy in Hambrug.
- ·3 t sittenOnly for those of you who don't know anything about the French market and would like to gain more knowledge. As is always the case in this industry, it's complicated, so it will be an ongoing process where we gradually become wiser about what's happening in France. There has been so much turbulence in Germany that, for my part, France has been pushed a bit into the background. But now that French politicians are returning from their summer holidays on Monday. And since everyone in Germany is taking a break, I thought I would take the opportunity to look into why PJ and TS have stated that they expect France to become a valuable market for Stenocare. Stenocare has two agreements in France. One is Institut des Cannabinoïdes Médicaux Français, the other is the distribution giant Movianto (see link below) Stenocare has, via ICMF, sent an application to HAS, because HAS has opened up for early application of medical cannabis. These companies have two different purposes. ICMF ICMF specializes in helping companies write applications, in this case, to the French "HAS" to ensure this is done correctly the first time. Movianto is one of the largest distributors in France. They state on their website: " leading specialist in supply chains within the healthcare and pharmaceutical sectors" What strikes me is that it is the pharmaceutical sector they specialize in. And as is well known, the devil is in the details. Movianto has approval to sell pharmaceutical and standardized medicines and not medical cannabis. Therefore, Astrum 10/10 can only be approved as a pharmaceutical and standardized medicine, and not cannabis medicine in France. The President has not signed yet, but it is expected to happen later and to be announced on October 1st. After that, the process towards final approval will proceed "ICMF" Their website is down, https://icmf.fr/ Movianto https://movianto.com/locations/france/ Announcement of cooperation with the above. https://www.inderes.dk/en/releases/stenocare-as-positions-for-first-mover-advantage-in-france-with-strategic-partnership-product-filing-and-national-distribution-partnership
- ·1 päivä sittenFrance has gone through a longer pilot project period, regarding medical cannabis. Concurrently, research has apparently been conducted into whether cannabis medicine could replace other medicine. They found out that it could. The study has proven that medical cannabis has reduced the consumption of opioids. After this study has emerged, French politicians have become more favorably disposed towards medical cannabis, therefore they want the pilot project to become a permanent scheme. For this reason, there will hardly be anyone who will put a spoke in the wheel to prevent the president from signing the decree, which is planned for this September. As I have written previously, flower medicine does not receive subsidies. But standardized oil, such as Astrum 10/10, will be approved for sale and receive 100% reimbursement. https://businessofcannabis.com/france-sets-july-deadline-for-medical-cannabis-regulations-as-withheld-study-shows-opioid-reductions/There is nothing decisively new to report about France. The post is only about 3D feeling a need to write something about stenocare every day and all the time.
- ·2 päivää sittenA bit of gossip from Germany while we wait for the batch to be released. There has just been a lawsuit in Frankfurt, where a woman wanted to have the opportunity to retain her status in the healthcare system regarding flower medicine. She did not win. By mistake or perhaps it was lobbying, it was also interpreted as if she and all others who had been treated with flower medicine after this ruling should be considered new patients, and then would have to go into quarantine anyway. This has been rectified again, and as of August 28th, a message has been sent out that these patient groups are free from quarantine. As long as those who have been treated with flowers before July 30th are free from quarantine, then it's good for Weeco Astrum10/10 because more bottles will be handed over the counter from this segment. https://bdcan.de/cannabisblueten-gkv/Admitted, I was cracking up, sorry. But it was good. I'm into good humor, after all
- ·28.8.I think it's a shame that this feed is completely polluted by 3D's assumptions and updates about inventory etc. It's very difficult to get an overview when there's incessant posting at all times. Could one perhaps just provide input once every 14 days? @3DSnehild, I think you should come up with some news yourself, I would welcome that, and I would also welcome others spending time to come up with news about this stock. I also think it's strange that you're angry that I spend time looking for news. Only because I have spent time looking for news, do you know that the flower medicine has lost its subsidy in Germany first on July 10th and later clarified as of July 29th, 2026. It is absolutely correct that it shouldn't have been me who broke this news. But it should have been the management who came with this news, because this news would most likely have an impact on the stock price, because Stenocare can now look forward to a larger income in Germany, which no one had expected, because this law of July 10th came suddenly, and therefore some of these will be prescribed Weeco Astrum 10/10 which is an unexpected income for Stenocare. But because it is me who broke this news and not Stenocare, it has naturally had no impact on the stock price. But if Stenocare had fulfilled their disclosure obligation, it would be likely that the stock price would have risen, due to this unexpected extra income. This has a name: asymmetric information. So yes, if Stenocare had come with this information instead of me, the stock would have been worth much more than it is now. You must take your complaints to the right place if you want it to be rectified, or keep quiet.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 763 | - | - | ||
| 19 000 | - | - | ||
| 1 000 | - | - | ||
| 1 000 | - | - | ||
| 3 363 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
No funds report this stock among their ten largest holdings.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 625 | 44 625 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 625 | 44 625 | 0 | 0 |
2026 Q2 -tulosraportti
Vain PDF
12 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 min sittenstock status Weed.de has for at least 3 weeks only had 3 pharmacies that have had the oil in stock. Now they have 4 pharmacies that have the oil in stock. I'm crossing my fingers that this is a sign that Weeco Pharma has succeeded in getting the batch released. The reason it has taken so long is that the German system that must approve the oil for sale is under pressure, after clarification on July 29. If the batch is not approved, then it must mean that this pharmacy has received approval to buy internally, probably the pharmacy in Hambrug.
- ·3 t sittenOnly for those of you who don't know anything about the French market and would like to gain more knowledge. As is always the case in this industry, it's complicated, so it will be an ongoing process where we gradually become wiser about what's happening in France. There has been so much turbulence in Germany that, for my part, France has been pushed a bit into the background. But now that French politicians are returning from their summer holidays on Monday. And since everyone in Germany is taking a break, I thought I would take the opportunity to look into why PJ and TS have stated that they expect France to become a valuable market for Stenocare. Stenocare has two agreements in France. One is Institut des Cannabinoïdes Médicaux Français, the other is the distribution giant Movianto (see link below) Stenocare has, via ICMF, sent an application to HAS, because HAS has opened up for early application of medical cannabis. These companies have two different purposes. ICMF ICMF specializes in helping companies write applications, in this case, to the French "HAS" to ensure this is done correctly the first time. Movianto is one of the largest distributors in France. They state on their website: " leading specialist in supply chains within the healthcare and pharmaceutical sectors" What strikes me is that it is the pharmaceutical sector they specialize in. And as is well known, the devil is in the details. Movianto has approval to sell pharmaceutical and standardized medicines and not medical cannabis. Therefore, Astrum 10/10 can only be approved as a pharmaceutical and standardized medicine, and not cannabis medicine in France. The President has not signed yet, but it is expected to happen later and to be announced on October 1st. After that, the process towards final approval will proceed "ICMF" Their website is down, https://icmf.fr/ Movianto https://movianto.com/locations/france/ Announcement of cooperation with the above. https://www.inderes.dk/en/releases/stenocare-as-positions-for-first-mover-advantage-in-france-with-strategic-partnership-product-filing-and-national-distribution-partnership
- ·1 päivä sittenFrance has gone through a longer pilot project period, regarding medical cannabis. Concurrently, research has apparently been conducted into whether cannabis medicine could replace other medicine. They found out that it could. The study has proven that medical cannabis has reduced the consumption of opioids. After this study has emerged, French politicians have become more favorably disposed towards medical cannabis, therefore they want the pilot project to become a permanent scheme. For this reason, there will hardly be anyone who will put a spoke in the wheel to prevent the president from signing the decree, which is planned for this September. As I have written previously, flower medicine does not receive subsidies. But standardized oil, such as Astrum 10/10, will be approved for sale and receive 100% reimbursement. https://businessofcannabis.com/france-sets-july-deadline-for-medical-cannabis-regulations-as-withheld-study-shows-opioid-reductions/There is nothing decisively new to report about France. The post is only about 3D feeling a need to write something about stenocare every day and all the time.
- ·2 päivää sittenA bit of gossip from Germany while we wait for the batch to be released. There has just been a lawsuit in Frankfurt, where a woman wanted to have the opportunity to retain her status in the healthcare system regarding flower medicine. She did not win. By mistake or perhaps it was lobbying, it was also interpreted as if she and all others who had been treated with flower medicine after this ruling should be considered new patients, and then would have to go into quarantine anyway. This has been rectified again, and as of August 28th, a message has been sent out that these patient groups are free from quarantine. As long as those who have been treated with flowers before July 30th are free from quarantine, then it's good for Weeco Astrum10/10 because more bottles will be handed over the counter from this segment. https://bdcan.de/cannabisblueten-gkv/Admitted, I was cracking up, sorry. But it was good. I'm into good humor, after all
- ·28.8.I think it's a shame that this feed is completely polluted by 3D's assumptions and updates about inventory etc. It's very difficult to get an overview when there's incessant posting at all times. Could one perhaps just provide input once every 14 days? @3DSnehild, I think you should come up with some news yourself, I would welcome that, and I would also welcome others spending time to come up with news about this stock. I also think it's strange that you're angry that I spend time looking for news. Only because I have spent time looking for news, do you know that the flower medicine has lost its subsidy in Germany first on July 10th and later clarified as of July 29th, 2026. It is absolutely correct that it shouldn't have been me who broke this news. But it should have been the management who came with this news, because this news would most likely have an impact on the stock price, because Stenocare can now look forward to a larger income in Germany, which no one had expected, because this law of July 10th came suddenly, and therefore some of these will be prescribed Weeco Astrum 10/10 which is an unexpected income for Stenocare. But because it is me who broke this news and not Stenocare, it has naturally had no impact on the stock price. But if Stenocare had fulfilled their disclosure obligation, it would be likely that the stock price would have risen, due to this unexpected extra income. This has a name: asymmetric information. So yes, if Stenocare had come with this information instead of me, the stock would have been worth much more than it is now. You must take your complaints to the right place if you want it to be rectified, or keep quiet.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 763 | - | - | ||
| 19 000 | - | - | ||
| 1 000 | - | - | ||
| 1 000 | - | - | ||
| 3 363 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
No funds report this stock among their ten largest holdings.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 625 | 44 625 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 625 | 44 625 | 0 | 0 |